This initiative addresses a translational gap in therapeutic discovery and development that exists between the preclinical screening pipeline and early experimental medicine studies in humans. Support would be provided for collaborative teams focused on developing, evaluating, and optimizing clinically meaningful and biologically-based measures that tap into functional domains to inform therapeutic development. Studies would evaluate the alignment or divergence of measures across preclinical screening and into healthy humans. Ideally, the initiative would illuminate the types of preclinical data and approaches that may be useful (or not useful) in predicting effects in humans based on biological conservation of signaling pathways and circuits, and provide tools needed to test novel therapeutic targets or mechanisms in animals and in humans.
via NIMH | Recent Updates http://ift.tt/1yy9nHD